The primary function of the kidney is to eliminate excess fluid and waste from circulation. When the kidneys are not functioning properly, dialysis is employed to do this procedure. Waste substances like urea and creatinine are eliminated from circulation through artificial and natural semi-permeable membranes. Hemodialysis employs an artificial membrane to purify the blood, as opposed to peritoneal dialysis, which uses the peritoneum in the abdomen as a biologically semi-permeable membrane. The prevalence of end-stage renal diseases, incidences of diabetes and hypertension, and financing for the development of new technology are the main drivers influencing the expansion of the dialysis industry.
Since the transplant procedure is thought to be foreign to the human body, kidney transplantation requires a large operation, a donor match, and a lifetime prescription of immunosuppressant medications to prevent body rejection against the organ. These drugs may harm patients' health by increasing the risk of diabetes, cancer, and severe infections. It is often not an option for a patient with a history of cancer, dementia, excessive obesity, or drug or alcohol addiction. Therefore, these traits make people less likely to choose a kidney transplant.
Home hemodialysis (HHD) is a more suitable type of hemodialysis than in-center hemodialysis because of its patient-centeredness and efficiency (ICHD). Pharmaceutical businesses are anticipated to engage significantly in patient and clinician education regarding home dialysis over the next ten years due to the increasing popularity of HHD in several countries. This resurgence of home dialysis is attributed to the development of user-friendly operating systems like the NxStage System One equipment and ostensible studies showing better outcomes for patients getting HHD than those receiving ICHD. According to projections, this shift in consumer preferences will provide HHD with exciting new business opportunities, helping the dialysis market grow.
Asia-Pacific is the most significant shareholder in the global dialysis market and is expected to grow at a CAGR of 6.10% during the forecast period. Asia-Pacific offers profitable potential for dialysis market players because of its sizeable population, various chronic and lifestyle diseases, and swift rise in ESRD prevalence. Chronic and lifestyle conditions like hypertension, diabetes, chronic glomerulonephritis, and autoimmune diseases are also common in Asia-Pacific, resulting in poor treatment outcomes. These conditions are caused by low gross domestic products in developing countries, inadequate funding for healthcare, and a higher percentage of patients living below the poverty line.
North America is anticipated to grow at a CAGR of 3.80% generating USD 35,253.25 million during the forecast period. Due to renal diseases (mostly ESRD and CKD), greater public awareness of home dialysis, and the region's well-established healthcare infrastructure, it is projected that the region's dialysis industry will grow during the forecast period. Additionally, recent trends show a decrease in the hospitalization rate for dialysis patients with ESRD and CKD. A substantial portion of this was caused by increased awareness of at-home dialysis procedures and changes to local laws.
Europe is the second-largest market contributor to the global market because of the region's expanding patient population—including those with ESRD and CKD—high patient disposable income, stable healthcare infrastructure, and patients' high spending money. It is anticipated that the population affected by chronic renal diseases and the prevalence of ESRD disease will rise dramatically due to a shift in demographic patterns among the European population, where most individuals are getting older.